Unlock this StockReport nowClick to Unlock

Regeneus Share Price

RGS A$0.079 -0.0  -8.1%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 30th Jun 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue A$m
Operating Profit A$m
Net Profit A$m
EPS Reported AUD¢
EPS Normalised AUD¢
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps AUD¢
Capex ps AUD¢
Free Cashflow ps AUD¢
Dividend ps AUD¢
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc A$m
Working Capital A$m
Net Fixed Assets A$m
Net Debt A$m
Book Value A$m
Average Shares m
Book Value ps AUD¢

FINANCIAL BRIEF: For the six months ended 31 December 2018, Regeneus Ltd revenues decreased 96% to A$15K. Net loss decreased 2% to A$2.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development expenses decrease of 39% to A$1.3M (expense), Corporate Expenses decrease of 14% to A$1.6M (expense), Occupancy Expenses decrease of 1% to A$236K (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Dec '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
30th Jun 2019
30th Jun 2020

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (A$) (¢) (¢) (A$) (¢) (¢)
Consensus Estimate
1m Change
3m Change
1 broker Broker Consensus Trend
Broker Recommendations for Regeneus
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Edison Investment Research Dennis Hulme ,

Profile Summary

Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.

Directors: Leo Lee (CEO) , John Bird (CFO) , Graham Vesey (CSO) , Sandra McIntosh (DHR) , Charlotte Morgan (OTH) , Duncan Thomson (OTH) , Barry Sechos (NEC) , John Chiplin (NID) 60, Alan Dunton (NID) 62, Glen Richards (NID) ,

No. of Employees: n/a No. of Shareholders: n/a

Last Annual June 30th, 2018
Last Interim December 31st, 2018
Incorporated August 14, 2007
Public Since September 18, 2013
Shares in Issue 213,714,568
Free Float 144.9m (67.8%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Eligible for an ISA? a SIPP?

Address Ground floor 25 Bridge St, PYMBLE, 2073, Australia
Web http://www.regeneus.com.au/
Phone +61 2 94998010
Contact ()
Auditors Grant Thornton Audit Pty Ltd

RGS Share Price Performance RGS Share Price Quote
-0.0  -8.1%
Traded 6:10am · Minimum 15 min delayed · NMS:

Latest RGS News Announcements (delayed)

Upcoming RGS Events

Recent ↓
Thursday 22nd November, 2018
Regeneus Ltd Annual Shareholders Meeting
Wednesday 31st October, 2018
Regeneus Ltd at AusBiotech Life Sciences Conference
Thursday 30th August, 2018
Full Year 2018 Regeneus Ltd Earnings Release
Tuesday 22nd August, 2017
Preliminary 2017 Regeneus Ltd Earnings Release
Wednesday 22nd February, 2017
Interim 2017 Regeneus Ltd Earnings Release
Monday 7th November, 2016 (estimate)
Regeneus Ltd Annual Shareholders Meeting
Sunday 8th November, 2015
Regeneus Ltd Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy RGS

Access RGS Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis